Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CCR1 | P32246 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24069429 | 0.94 | SLC6A2 (0.63) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL25290527 | 0.90 | SLC6A2 (0.59) | HTR7SLC6A2SLC6A4KMT2AHTT | |
| SCHEMBL25758526 | 0.90 | CCR3 (0.58) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL25758544 | 0.90 | MEN1 (0.69) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL30376178 | 0.89 | HTR7 (0.69) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL25759699 | 0.87 | HTR7 (0.59) | HTR7SLC6A2SLC6A4KMT2AHTT | |
| SCHEMBL25758458 | 0.87 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3KMT2AHTT | |
| SCHEMBL24070124 | 0.86 | MEN1 (0.60) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL25758331 | 0.84 | MEN1 (0.58) | HTR7SLC6A2SLC6A4SLC6A3KMT2A | |
| SCHEMBL29022584 | 0.83 | SMN1; SMN2 (0.57) | HTR7SLC6A2SLC6A4SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| EP-4159718-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | HTR7 79/4885SLC6A2 1/4885SLC6A4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.